CD274 and non-small cell lung carcinoma: Use of checkpoint inhibitors targeting PD-1 or PD-L1 either alone or in different combinations with standard platinum-based chemotherapy or with another checkpoint inhibitor (with or without chemotherapy) has shown improved survival over standard platinum-based chemotherapy as frontline treatment in advanced non-oncogene driven NSCLC [1,2,3,4,5,6,7,8,9,10,11,12].